| Monopolar (n = 73) | Bipolar (n = 73) | P value |
---|---|---|---|
Age | 70 (31–87, 13) | 69 (38–85, 16) | 0.994 |
Sex (male/female) | 52/21 | 51/22 | 0.856 |
BMI | 22.2 (15.4–32.2, 4.20) | 22.8 (15.9–37.1, 4.50) | 0.768 |
ASA (1/2/3) | 5/56/12 | 9/54/10 | 0.506 |
Diagnosis (HCC/CCC/meta/biliary tract cancer/benign disease/other) | 41/7/15/2/8/0 | 46/4/15/3/5/0 | 0.246 |
Background liver disease (normal/HCV/HBV/ASH/NASH/other) | 35/22/6/3/4/3 | 30/28/8/2/3/2 | 0.475 |
Liver fibrosisa (f0–1, f2–4) | 29/33 | 23/38 | 0.309 |
Type of resection (partial/lateral/subsegmentectomy/segmentectomy/hemihepatectectomy/trisegmentectomy) | 17/1/25/10/20/0 | 18/1/25/10/19/0 | 0.433 |
Number of resected lesions | 1 (1–16, 0) | 1 (1–3, 0) | 0.365 |
Size of the largest nodule on preoperative imagingb (cm) | 2.7 (0.9–20, 3.0) | 2.4 (0.5–10, 1.9) | 0.147 |
Number of nodules on preoperative imagingb | 1 (1–10, 0) | 1 (1–10, 1) | 0.513 |
Lymph node dissection (yes/no) | 11/62 | 9/64 | 0.630 |
Biliary reconstruction (yes/no) | 5/68 | 6/67 | 0.754 |
Intraoperative drain insert (yes/no) | 73/0 | 72/1 | 0.500 |
Duration of drain placement | 4 (0–131, 4) | 5 (2–94, 3) | 0.112 |
Neoadjuvant chemotherapy (yes/no/previous) | 10/62/1 | 11/60/2 | 0.584 |
Total bilirubin (mg/dL) (≥ 1.1/ < 1.1) | 16/57 | 17/56 | 0.843 |
Aspartate transaminase (IU/L) (≥ 31/ < 31) | 36/37 | 38/35 | 0.741 |
Albumin (g/dL) (≥ 3.9/ < 3.9) | 26/47 | 26/47 | 1.000 |
Prothrombin activity (%) (≥ 69/ < 69) | 69/4 | 71/2 | 0.340 |
Activated partial thromboplastin time (%) (≥ 69/ < 69) | 62/11 | 65/8 | 0.461 |
Hemoglobin (g/dL) (≥ 11.4/ < 11.4) | 58/15 | 59/14 | 0.836 |
Platelet (× 104/μL) (≥ 15.3/ < 15.3) | 45/28 | 43/30 | 0.735 |
Blood urea nitrogen (mg/dL) (≥ 20.0/ < 20.0) | 11/62 | 10/63 | 0.814 |
Creatinine (mg/dL) (≥ 1.07/ < 1.07) | 14/59 | 9/64 | 0.256 |
C-reactive proteinc (mg/dL) (≥ 0.14/ < 0.14) | 28/43 | 22/35 | 0.923 |
ICGR15d (%) (≥ 10/ < 10) | 45/25 | 45/25 | 0.557 |
Child–Pugh score | 5 (5–6, 0) | 5 (5–8, 0) | 0.084 |